Related Experiment Videos
In the grip of the python: conflicts at the university-industry interface
1North Wales Dept of Psychological Medicine, University of Wales College of Medicine, Hergest Unit, Bangor LL57 2PW, United Kingdom. Healy_Hergest@compuserve.com
Science and Engineering Ethics
|March 21, 2003
Summary
Academic freedom concerns arose when a university contract was withdrawn, linked to debates on selective serotonin reuptake inhibitor (SSRI) antidepressants potentially triggering suicidality. Evidence suggests data manipulation and ghostwriting by pharmaceutical companies influence research.
Area of Science:
- Psychopharmacology
- Academic Freedom
- Clinical Trials
Background:
- A contract withdrawal by the University of Toronto in 2000 sparked a dispute over academic freedom.
- This case is linked to the ongoing debate regarding the potential of selective serotonin reuptake inhibitors (SSRIs) to induce suicidality in patients.
Purpose of the Study:
- To investigate the academic freedom infringements related to the SSRI suicidality debate.
- To examine concerns regarding pharmaceutical industry practices in clinical trial data dissemination and publication.
Main Methods:
- Analysis of events following a contract withdrawal and subsequent legal action.
- Review of evidence concerning pharmaceutical company data handling and ghostwriting in therapeutics.
Main Results:
- Evidence suggests potential miscoding of raw data on suicidal acts and ideation by pharmaceutical companies.
- Concerns are raised about the prevalence of ghostwriting in scientific articles within the therapeutics domain.
- The case highlights issues of pharmaceutical companies restricting public access to clinical trial data.
Conclusions:
- The case underscores the critical intersection of academic freedom, pharmaceutical industry practices, and public access to clinical trial data.
- There are significant concerns about the integrity of research and publication in psychopharmacology due to corporate influence.